Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Delayed Quote USD

Genprex, Inc. (GNPX)

Compare
0.2665
+0.0015
+(0.57%)
At close: 4:00:01 PM EDT
0.2667
+0.00
+(0.08%)
After hours: 4:51:47 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for GNPX

Recent News: GNPX

View More
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
PR Newswire 16 days ago
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
PR Newswire 17 days ago
Genprex to Participate at BIO Europe Spring 2025

Genprex to Participate at BIO Europe Spring 2025
PR Newswire last month
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
PR Newswire last month
Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Provides Update on Diabetes Gene Therapy Program
PR Newswire last month
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
PR Newswire last month
Genprex doses first subject in expansion part of lung cancer gene therapy trial

Genprex doses first subject in expansion part of lung cancer gene therapy trial
Clinical Trials Arena 2 months ago
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
PR Newswire 2 months ago
Genprex Advances Cancer Trials and Diabetes Therapy

Genprex Advances Cancer Trials and Diabetes Therapy
TipRanks 2 months ago
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire 3 months ago
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
PR Newswire 3 months ago
View More

Related Tickers

PTIX Protagenic Therapeutics, Inc.
0.3000
+15.92%
 
HEPA Hepion Pharmaceuticals, Inc.
0.4220
-2.11%
 
ENTO Entero Therapeutics, Inc.
0.3899
-3.25%
 
APVO Aptevo Therapeutics Inc.
1.0100
+2.99%
 
CDT Conduit Pharmaceuticals Inc.
0.9101
-14.94%
 
OSRH OSR Holdings, Inc.
1.4400
-2.04%
 
RNAZ TransCode Therapeutics, Inc.
0.4040
+1.35%
 
ZVSA ZyVersa Therapeutics, Inc.
0.7700
-0.17%
 
ALLR Allarity Therapeutics, Inc.
0.7312
+0.84%
 
IBO Impact BioMedical Inc.
0.4951
-2.92%